 |
20 |
 |
| |
Components and major actions of the renin angiotensin system
|
|
 |
|
 |
|
|
21 |
|
| |
Vasculoprotective effects of angiotensin-(1-7)
|
|
|
|
|
|
|
22 |
|
| |
ACE metabolizes Ang-(1-7) into Ang-(1-5): Effect with and without ACE inhibition
|
|
|
|
|
|
|
23 |
|
| |
ACE and endothelial function
|
|
|
|
|
|
|
24 |
|
| |
Mechanisms for the effects of ACE inhibition on endothelial dysfunction
|
|
|
|
|
|
|
25 |
|
| |
Potential benefits of suppressing cardiac ACE
|
|
|
|
|
|
|
26 |
|
| |
Mechanisms of cardiac RAS activation in cardiac remodeling
|
|
|
|
|
|
|
27 |
|
| |
Possible mechanisms of endothelial dysfunction in heart failure
|
|
|
|
|
|
|
28 |
|
| |
Effect of experimental heart failure on cardiac ACE activity
|
|
|
|
|
|
|
29 |
|
| |
Genetic evidence that cardiac ACE correlates with experimental infarct size
|
|
|
|
|
|
|
30 |
|
| |
Neointima formation: Correlation with blood pressure and residual serum and tissue ACE after ACE-I
|
|
|
|
|
|
|
31 |
|
| |
ACE inhibitors and fibrinolysis
|
|
|
|
|
|
|
32 |
|
| |
Vasculoprotective effects of tissue ACE inhibition
|
|
|
|
|
|
|
33 |
|
| |
Cardiovascular role of bradykinin as determined by knockout mice
|
|
|
|
|
|
|
34 |
|
| |
ACE inhibition increases vasodilation by a bradykinin mechanism in response to flow-mediated dilation
|
|
|
|
|
|
|
35 |
|
| |
Effects of ACE-I vs other antihypertensive agents on endothelial function in hypertensive patients
|
|
|
|
|
|
|
36 |
|
| |
ACE inhibitors and endothelial function: Evidence for the role of NO and bradykinin
|
|
|
|
|
|
|
37 |
|
| |
ACE inhibitors upregulate b-adrenergic receptors on cardiac myocytes by a bradykinin mechanism
|
|
|
|
|
|
Resources
